Cloud-Clone promotes customizable multi-factor protein detection kits to researchers

Cloud-Clone is promoting customizable multi-factor protein detection kits to help researchers overcome topic-selection bottlenecks, the company said in a release issued from Houston on October 19, 2026. The kits cover 7,000 targets across more than 10 species and allow custom panels, according to the release. EIN Presswire published the announcement.

Cloud-Clone's Multi-Factor Assay Kits

Cloud-Clone said many researchers struggle to find original topics and publishable ideas even in well-funded labs. The company argued that researchers often get stuck recycling established pathways, markers and animal models instead of generating original research angles. Its multi-factor suspension array kits are designed to help investigators capture unexpected signals during exploratory work, the company said.

For inflammatory disease models, the kits can measure cytokines, chemokines, growth factors and other inflammatory markers in one test. For cross-species mechanistic studies, the panels can combine human, mouse, rat and other targets for comparison. Researchers can build custom panels with freely chosen targets instead of being limited to fixed commercial kits, and panels can be reconfigured as studies progress and preliminary results emerge, according to the release.

Cloud-Clone said its reagent R&D spans nearly 20 years. The company said its protein and antibody resources cover 7,000 targets across more than 10 species. The release framed multi-factor detection as a shift from following published markers to measuring what a project actually needs.

Cloud-Clone's Platform and Distribution Records

According to akta.pro company records, Cloud-Clone launched a proprietary high-sensitivity flow cytometry-based multiplex immunoassay platform with magnetic bead technology and 7,000+ validated antibody pairs in February 2026, reducing detection time from about three days to about two hours. The same records show the company maintains a global distributor network for its research reagents and products, with distribution across multiple countries including the United States, United Kingdom, France and Japan. Cloud-Clone products have supported over 42,000 SCI-indexed publications as of end-2025, the records state.

Earlier Cloud-Clone Assay Launches

In September 2026, Cloud-Clone released a 13-plex bone-metabolism detection panel using Luminex technology to quantify 13 biomarkers across six dimensions, requiring only 25 μL of sample, EIN Presswire reported. In August 2026, the company launched an 11-plex multiplex assay kit for immune and inflammation research that requires only 50 μL of sample to quantify 11 biomarkers simultaneously, according to EIN Presswire. Also in August 2026, Cloud-Clone launched a full-lineage multi-species primary neural cell portfolio covering ten species, including humans, mice, and large animals like dogs and cats, EIN Presswire reported.

Cloud-Clone's Next Steps

Cloud-Clone said it will continue optimizing multi-factor detection capabilities for exploratory research. The company is encouraging researchers to use broader screening and deeper data analysis to identify new disease mechanisms, biomarkers and targets from valuable samples.